CPI and Quotient Sciences Launch Joint Venture to Accelerate RNA Drug Development

CPI, a key innovation partner at NETPark, has signed a memorandum of understanding with Quotient Sciences to form a new joint venture aimed at speeding up the development of RNA-based medicines.

The collaboration will combine CPI’s capabilities in small-scale RNA manufacturing and lipid nanoparticle (LNP) formulation with Quotient Sciences’ Translational Pharmaceutics® platform. This integrated approach will streamline the journey from DNA to clinical trials—reducing timelines to as little as two months.

The joint venture will offer a seamless solution for mRNA synthesis, LNP formulation, clinical manufacturing, and early-phase testing. This is expected to significantly improve the speed and flexibility of RNA therapeutic development, particularly in areas where delivery is critical to success.

This marks the first time Translational Pharmaceutics®—used in over 500 global drug development programs—will be applied to mRNA-based therapies.

CPI CEO Frank Millar said the partnership represents “a bold step forward for the RNA ecosystem,” while Quotient Sciences CEO Thierry Van Nieuwenhove called it “a pivotal moment” for the field.

With NETPark’s growing reputation as a hub for advanced therapeutics, this venture highlights the region’s role in shaping the future of global healthcare innovation.